← Leaderboards
Somasundar Prasad Gabbita
Phase 2 Discovery, Inc.
$5,653,311
Attributed
$7,608,015
Total exposure
16
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $872.1K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,608,015 · 16
By mechanism
R43$3,121,901 · 12
R44$2,838,668 · 3
SB1$1,647,446 · 1
Top collaborators
- Marni E Harris-White4 shared
- Russell W Brown2 shared
- Sridhar Varadarajan2 shared
- Ying Liang1 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPharmaceutical PreparationsSmall Business Innovation Research GrantLeadDoseInhibitor/AntagonistIn VitroAdverse EffectsPathologyProteinsFda ApprovedChronicAffectNeurologicPreclinical StudyNeuroinflammationOralMouse ModelFunctional DisorderCognitive FunctionRattusCytokineDisease ProgressionS Disease
Grant awards (21)
A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD$374,169
R44 · FY2022 · AG · contact PI
A first-in-class orally bioavailable small molecule dual inhibitor targeting NLRP3 and the dopamine transporter to treat AD$470,041
R44 · FY2021 · AG · contact PI
Targeting Latexin for radiation mitigation.$284,306
R43 · FY2020 · AI · contact PI
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment$416,247
SB1 · FY2019 · AG · contact PI
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$166,732
R44 · FY2019 · AG · contact PI
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment$534,299
SB1 · FY2018 · AG · contact PI
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$337,833
R44 · FY2018 · AG · contact PI
A Novel Small Molecule TNF-alpha Inhibitor as a Disease-Modifying Alzheimer's Disease Drug Treatment$696,900
SB1 · FY2017 · AG · contact PI
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.$744,572
R44 · FY2016 · AG · contact PI
A Novel Small molecule TNF-alpha inhibitor as a disease-modifying AD drug treatment.$745,321
R44 · FY2015 · AG · contact PI
A first-in-class orally active anti-TNF-alpha inhibitor to treat AD$395,476
R43 · FY2013 · AG · contact PI
A Novel Small molecule TNF?? inhibitor as a disease-modifying AD drug treatment.$390,959
R43 · FY2012 · AG · contact PI
A rapid microfluidic P.O.C CNS biomarker platform to predict delayed HICP onset.$348,668
R43 · FY2012 · NS · contact PI
PD2005: A CNS active DAT inhibitor for improving cognitive deficits in traumatic$263,333
R43 · FY2011 · NS · contact PI
PD2024: A Peripherally Active TNFalpha inhibitor for the treatment of Obesity$272,082
R43 · FY2010 · DK · contact PI
Thiothalidomides as neuroprotectant drugs for PD.$358,216
R43 · FY2007 · NS · contact PI
Neuroprotective efficacy of a melatonin analog in traumatic brain injury$177,363
R43 · FY2006 · NS · contact PI
Thiothalidomides as neuroprotectants drugs for ALS$238,026
R43 · FY2005 · NS
GIR Antagonists: Novel Feeding/Catabolism Molecules$174,407
R43 · FY2005 · DK
Biomarker of Neuroprotectant Efficacy in ALS$119,065
R43 · FY2003 · NS
Biomarker of Neuroprotectant Efficacy$100,000
R43 · FY2002 · NS